Case Report
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1829-1834
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1829
Figure 1
Figure 1 Serial cell-free DNA analyses and carcinoembryonic antigen levels over time. Osimertinib was initiated in February 2022, and imaging in April 2022 confirmed treatment response with a decrease in size of the hepatic metastases. CEA: Carcinoembryonic antigen; CEGFR: Epidermal growth factor receptor; VAF: Variant allele frequency.